Privately held theranostics company developing monoclonal antibodies against cancer-specific and other disease-specific targets for therapeutic and diagnostic products
Privately held theranostics company developing monoclonal antibodies against cancer-specific and other disease-specific targets for therapeutic and diagnostic products. Its cancer-focused work includes companion diagnostics to support early detection, identify patients likely to respond to targeted therapies, predict recurrence, and monitor treatment response.